Search - tctmd.com

Displaying 501 - 520 of 872

Sort: Relevancy | Date

Presentation TCT 2014

Strokes After TAVR II: Management Considerations (Current and Future)

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Nicolas M. van Mieghem

September 14, 2014

Presentation TCT 2014

Strokes After TAVR I: Incidence (Past and Present) and Multifactorial Origin

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb

September 14, 2014

Presentation TCT 2014

Case #1: Significant Aortic Regurgitation After TAVR How to Treat?

Presenter: Graham A. Cassel, Hans R. Figulla, Greg L. Kaluza, Jochen Wöhrle, Jean Voster

September 14, 2014

Presentation TCT 2014

Valvular Heart Disease: Treatment of Mitral Stenosis and Mitral Regurgitation

Presenter: Michael J. Lim, Hemal Gada

September 14, 2014

News Conference News TCT 2014

TCT Course Director Outlines Current TAVR Controversies

September 14, 2014

News Conference News TCT 2014

Registry Data Show Promise of Valve-in-Valve TAVR in High-Risk Patients

September 14, 2014

Presentation TCT 2014

Case #1: TAVR with a Repositionable Device: Does Multiple Repositioning Avoid Paravalvular Aortic Regurgitation?

Presenter: Markus Kasel, Joachim Schofer

September 13, 2014

Presentation TCT 2014

Role of Exercise and Viability in the Evaluation of Mitral Regurgitation

Presenter: Paul A. Grayburn, Robert J. Siegel, Scott Lim, Maurice E. Sarano

September 13, 2014

Presentation TCT 2014

Echocardiography of Mitral Regurgitation: A Critical Appraisal of Quantification and Prognostic Impact

Presenter: Paul A. Grayburn, Robert J. Siegel, Scott Lim

September 13, 2014

Presentation TCT 2014

Setting the Stage: Most Important Mitral Regurgitation Studies and Events of the Last 12 Months

Presenter: Blase A. Carabello, Allan Schwartz, Charles J. Davidson, Gregg W. Stone

September 13, 2014

Presentation TCT 2014

Updated US and EU Mitral Guidelines: Where Do They Agree and Disagree (and Why)?

Presenter: Blase A. Carabello, Allan Schwartz, Charles J. Davidson, Robert O. Bonow

September 13, 2014

Presentation TCT 2014

TCT 788: Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High-Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Presenter: Blase A. Carabello, Allan Schwartz, Charles J. Davidson, Saibal Kar

September 13, 2014

Presentation TCT 2014

Just How Effective Is Biventricular Pacing for Functional Mitral Regurgitation?

Presenter: Blase A. Carabello, Allan Schwartz, Charles J. Davidson, Anita Asgar

September 13, 2014

Presentation TCT 2014

Prognosis of Secondary MR in Heart Failure: New Insights from the Italian Registry

Presenter: Blase A. Carabello, Allan Schwartz, Charles J. Davidson, Francesco Maisano

September 13, 2014

Presentation TCT 2014

Primary vs Secondary Mitral Regurgitation: Two Different Diseases with Different Etiologies, Prognostic Impact, and Therapies

Presenter: Blase A. Carabello, Allan Schwartz, Charles J. Davidson, Jeffrey S. Borer

September 13, 2014

Presentation TCT 2014

Mitralign: Percutaneous Annuloplasty for Tricuspid Regurgitation

Presenter: Alec S. Vahanian, Scott Lim

September 13, 2014

Presentation TCT 2014

TCT 691: Clinical Impact of the Presence of Aortic Regurgitation Following Transcatheter Aortic Valve Replacement: Insights Into the Degree and Acuteness of Presentation

Presenter: Valentin Fuster, Marina Urena, MD

September 13, 2014

Presentation TCT 2014

Tricuspid Regurgitation: Natural History and Surgical Indications and Outcomes

Presenter: Alec S. Vahanian, James S. Gammie

September 13, 2014

Presentation TCT 2014

Hemodynamics of Mitral Regurgitation and Live Calculations Using the Telestrator

Presenter: Thomas H. Maloney, John R. Zimmerman, Jeff Davis

September 13, 2014

News Conference News TCT 2014

Moderate-to-Severe AR After TAVR May Yield Greater Mortality Risk

September 13, 2014

Advertisement

Strokes After TAVR II: Management Considerations (Current and Future)

Strokes After TAVR I: Incidence (Past and Present) and Multifactorial Origin

Case #1: Significant Aortic Regurgitation After TAVR How to Treat?

Valvular Heart Disease: Treatment of Mitral Stenosis and Mitral Regurgitation

TCT Course Director Outlines Current TAVR Controversies

Registry Data Show Promise of Valve-in-Valve TAVR in High-Risk Patients

Case #1: TAVR with a Repositionable Device: Does Multiple Repositioning Avoid Paravalvular Aortic Regurgitation?

Role of Exercise and Viability in the Evaluation of Mitral Regurgitation

Echocardiography of Mitral Regurgitation: A Critical Appraisal of Quantification and Prognostic Impact

Setting the Stage: Most Important Mitral Regurgitation Studies and Events of the Last 12 Months

Updated US and EU Mitral Guidelines: Where Do They Agree and Disagree (and Why)?

TCT 788: Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High-Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Just How Effective Is Biventricular Pacing for Functional Mitral Regurgitation?

Prognosis of Secondary MR in Heart Failure: New Insights from the Italian Registry

Primary vs Secondary Mitral Regurgitation: Two Different Diseases with Different Etiologies, Prognostic Impact, and Therapies

Mitralign: Percutaneous Annuloplasty for Tricuspid Regurgitation

TCT 691: Clinical Impact of the Presence of Aortic Regurgitation Following Transcatheter Aortic Valve Replacement: Insights Into the Degree and Acuteness of Presentation

Tricuspid Regurgitation: Natural History and Surgical Indications and Outcomes

Hemodynamics of Mitral Regurgitation and Live Calculations Using the Telestrator

Moderate-to-Severe AR After TAVR May Yield Greater Mortality Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content